Solveig LaTurner

Solveig LaTurner began their work experience as an Assistant Scientist at Oridigm in 1999. Solveig then worked as an Associate Scientist II at AMRI from 1999 to 2003, where they were responsible for purifying small molecule libraries and conducting high-throughput LC-MS analysis. From 2003 to 2004, LaTurner worked as an Associate Scientist III at Ceptyr, focusing on the purification of small molecule lead series and maintaining analytical instrumentation. Solveig then joined MDS Pharma Services in 2005 as a Scientist I, where they developed bioanalytical methods and managed contract research studies. During their time at MDS, they also obtained Lean Six Sigma Green Belt certification and implemented process improvement initiatives. In 2010, LaTurner briefly worked as a Scientist II at Ricerca Biosciences before joining the University of Washington in 2011 as a Research Scientist in the Department of Medicine's Nephrology division. Later that year, they transitioned to Gilead Sciences as an Associate Scientist II in Analytical Operations, where they developed high-resolution mass spectrometric methods and performed GMP testing of clinical drug substances and products. Solveig also generated and reviewed GMP documentation. After leaving Gilead Sciences in 2017, LaTurner joined Cascadian Therapeutics, Inc. as a Senior Quality Control Analyst, focusing on quality control activities. In 2018, LaTurner joined Seattle Genetics as a Quality Control Scientist, responsible for quality control-related tasks. Solveig'smost recent position was as the Director of Analytical Chemistry at Eidos Therapeutics, beginning in April 2019.

Solveig LaTurner holds a Bachelor of Science (BS) degree in Chemistry from the University of Washington.